Stock Detail
BIOMARIN PHARMACEUTICAL INC
Biotechnology
BMRN @ Yahoo Finance | BMRN Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $31.07 | $31.64 | $-0.58 | -1.83% | 0.00 | $31.65 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $31.39 | $31.01 | 420,578 | 3.55B | 979,591 | -124.28 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 31.87 | 31.47 | 31.24 | 30.84 | 30.61 |
Stock Profile
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of biopharmaceuticals and therapeutics for serious diseases and medical conditions. Its product portfolio comprises three approved products and various investigational product candidates. The company offers Aldurazyme, an enzyme replacement therapy for the treatment of mucopolysaccharidosis I, a progressive and debilitating life-threatening genetic disease that frequently results in death during childhood or early adulthood; Naglazyme, an enzyme replacement therapy for the treatment of mucopolysaccharidosis VI, an inherited, life-threatening lysosomal storage disorder; and Orapred, a drug primarily used to treat asthma exacerbations in children and other inflammatory conditions. BioMarin is also developing additional proprietary formulations of Orapred, including Orapred ODT (orally disintegrating tablets), which is under U.S. FDA review. In addition, the company is developing various other product candidates, including Phenoptin, a proprietary synthetic oral form of tetrahydrobiopterin for the treatment of moderate to mild forms of phenylketonuria (PKU); Phenylase, a preclinical-stage enzyme substitution therapy for the treatment of the more severe form of PKU; and 6R-BH4 for vascular dysfunction. BioMarin has a joint venture, BioMarin/Genzyme LLC, with Genzyme Corporation for the development and commercialization of Aldurazyme, as well as a strategic business partnership with Daiichi Suntory Pharma Co., Ltd. and Serono for Phenoptin, Phenylase and 6R-BH4 for cardiovascular indications. The company was founded in 1996 and is headquartered in Novato, California.